Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of a single dose of Aficamten (CK-274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model.

Journal of veterinary pharmacology and therapeutics - 1 Jan 2023

Sharpe Ashley N, Oldach Maureen S, Kaplan Joanna L, Rivas Victor, Kovacs Samantha L, Hwee Darren T, Morgan Bradley P, Malik Fady I, Harris Samantha P, Stern Joshua A

Abstract excerpt

Hypertrophic cardiomyopathy (HCM) is the most prevalent cardiac disease in cats and lacks efficacious preclinical pharmacologic intervention, prompting investigation of novel therapies. Genetic mutations encoding sarcomeric proteins are implicated in the development of HCM and small molecule myosin inhibitors are an emerging class of therapeutics designed to target the interaction of actin and myosin to alleviate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy, Hypertrophic
Share to Carrier Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cat Diseases

Share to Echocardiography

Share to Mutation

Share to Myocardial Contraction

Source

Open in PubMed Open full text

Identifiers

PMID: 36382714
DOI: 10.1111/jvp.13103
PMCID: PMC10099566

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of a single dose of Aficamten (CK-274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model.PMID 36382714Read ↗

Hypertrophic cardiomyopathy in purpose-bred cats with the A31P mutation in cardiac myosin binding protein-C.Semantic proximity Read ↗

Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy.Semantic proximity Read ↗

The Maine Coon Cat Harboring the MYBPC3-A31P Mutation: A Genotype-Stratified Phenotypic Characterization of Hypertrophic CardiomyopathySemantic proximity Read ↗

A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy.Semantic proximity Read ↗

Genetic Basis of Hypertrophic Cardiomyopathy in CatsSemantic proximity Read ↗

Danicamtiv increases myosin recruitment and alters the chemomechanical cross bridge cycle in cardiac muscleSemantic proximity Read ↗

Ulacamten: A Novel, RLC-Targeting Cardiac Myosin Inhibitor for Potential Treatment of Cardiac Hypercontractility, Including HFpEFSemantic proximity Read ↗

Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy.Semantic proximity Read ↗

Familial hypertrophic cardiomyopathy in maine coon cats: an animal model of human disease.Semantic proximity Read ↗

In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitorSemantic proximity Read ↗

Prospective echocardiographic and tissue Doppler imaging screening of a population of Maine Coon cats tested for the A31P mutation in the myosin-binding protein C gene: a specific analysis of the heterozygous status.Semantic proximity Read ↗

Genotype-phenotype correlation between the cardiac myosin binding protein C mutation A31P and hypertrophic cardiomyopathy in a cohort of Maine Coon cats: a longitudinal study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.